Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Inclusion Criteria: * Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed) * Presence of measurable disease * Age \>=18 years * ECOG performance status 0-1 * Negative pregnancy test (if female in reproductive years) * Use of effective contraceptive methods if men and women of child producing potential * Adequate liver function Total Serum Bilirubin \<=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) \<=2.5ULN (if liver metastases are present, then \<=5ULN is allowed) ALP \<=2.5ULN (if liver and/or bone metastases are present, then \<=5ULN is allowed) * Adequate renal function Serum Creatinine \<=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula \> 60 mL/min. * Adequate hematologic status ANC \>=1,500cells/mm3 Platelet Count \>=100,000cells/mm3 Hemoglobin \>=9.0g/dL * Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated) * Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade \<=1 Exclusion Criteria: * Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis * Grade \>1 retinopathy * Known brain metastases * Known active infections * Pregnant or breast feeding women * Diabetes mellitus uncontrolled * Gastrointestinal disease that would impact on drug absorption * Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline * Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study